Cosentyx (secukinumab) is a medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the sources provided, there is limited information available on the safety of Cosentyx use during pregnancy.
The drug patent information provided by Drug Patent Watch [1] indicates that the use of Cosentyx during pregnancy may cause harm to the fetus based on animal studies. However, there are no adequate and well-controlled studies in pregnant women to determine the drug's safety. Therefore, the use of Cosentyx during pregnancy is not recommended unless the potential benefits outweigh the potential risks.
A study published in the National Center for Biotechnology Information [2] evaluated the safety of Cosentyx use during pregnancy. The study included 17 pregnant women who were exposed to Cosentyx during their pregnancy. The results showed that there were no major malformations or adverse outcomes in the newborns. However, the study had a small sample size, and further studies are needed to evaluate the safety of Cosentyx use during pregnancy.
The American College of Rheumatology [3] also recommends avoiding the use of Cosentyx during pregnancy unless the potential benefits outweigh the potential risks. They suggest that women of childbearing age should use contraception while taking Cosentyx and for at least 20 weeks after the last dose.
In conclusion, the available information suggests that the safety of Cosentyx use during pregnancy is uncertain. Animal studies indicate potential harm to the fetus, and there are limited human studies available. Therefore, the use of Cosentyx during pregnancy should be avoided unless the potential benefits outweigh the potential risks. Women of childbearing age should use contraception while taking Cosentyx and for at least 20 weeks after the last dose.
Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013855/
[3] https://rheumatology.org/patients/secukinumab-cosentyx